Else Marie Agger
Overview
Explore the profile of Else Marie Agger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
3174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mortensen R, Clemmensen H, Woodworth J, Therkelsen M, Mustafa T, Tonby K, et al.
Commun Biol
. 2024 May;
7(1):662.
PMID: 38811662
No abstract available.
2.
Aagaard C, Knudsen N, Sohn I, Izzo A, Kim H, Kristiansen E, et al.
J Immunol
. 2020 Sep;
205(8):2146-2155.
PMID: 32887748
Despite the fact that the majority of people in tuberculosis (TB)-endemic areas are vaccinated with the Bacillus Calmette-Guérin (BCG) vaccine, TB remains the leading infectious cause of death. Data from...
3.
Filskov J, Andersen P, Agger E, Bukh J
Sci Rep
. 2019 Oct;
9(1):14085.
PMID: 31575882
Despite recent treatment advances for chronic hepatitis C virus (HCV) infection, a vaccine is urgently needed for global control of this important liver pathogen. The lack of robust immunocompetent HCV...
4.
Mortensen R, Clemmensen H, Woodworth J, Therkelsen M, Mustafa T, Tonby K, et al.
Commun Biol
. 2019 Aug;
2:288.
PMID: 31396568
Tuberculosis, caused by infection with (Mtb), kills over 1.6 million people each year despite availability of antibiotics. The increase in drug resistant Mtb strains is a major public health emergency...
5.
Woodworth J, Christensen D, Cassidy J, Agger E, Mortensen R, Andersen P
Mucosal Immunol
. 2019 Feb;
12(3):816-826.
PMID: 30760832
T cell-mediated protection against Mycobacterium tuberculosis (Mtb) is dependent upon the ability to localize within the site of pulmonary infection and directly interact with infected cells. In turn, vaccine strategies...
6.
Billeskov R, Lindenstrom T, Woodworth J, Vilaplana C, Cardona P, Cassidy J, et al.
Front Immunol
. 2018 Jan;
8:1973.
PMID: 29379507
(Mtb), the etiologic agent of tuberculosis (TB), causes 1.8M deaths annually. The current vaccine, BCG, has failed to eradicate TB leaving 25% of the world's population with latent Mtb infection...
7.
Lindenstrom T, Moguche A, Damborg M, Agger E, Urdahl K, Andersen P
EBioMedicine
. 2017 Dec;
27:27-39.
PMID: 29249639
Despite inducing strong T cell responses, Mycobacterium tuberculosis (Mtb) infection fails to elicit protective immune memory. As such latently infected or successfully treated Tuberculosis (TB) patients are not protected against...
8.
Wilk Michelsen S, Soborg B, Diaz L, Hoff S, Agger E, Koch A, et al.
PLoS One
. 2017 Jun;
12(6):e0177906.
PMID: 28570574
Objective: Understanding human immunity to Mycobacterium tuberculosis (Mtb) during different stages of infection is important for development of an effective tuberculosis (TB) vaccine. We aimed to evaluate immunity to Mtb...
9.
Filskov J, Mikkelsen M, Hansen P, Christensen J, Thomsen A, Andersen P, et al.
J Virol
. 2017 Apr;
91(14).
PMID: 28446674
Despite the introduction of effective drugs to treat patients with chronic hepatitis C virus (HCV) infection, a vaccine would be the only means to substantially reduce the worldwide disease burden....
10.
Ruhwald M, de Thurah L, Kuchaka D, Zaher M, Salman A, Abdel-Ghaffar A, et al.
Sci Rep
. 2017 Apr;
7:45969.
PMID: 28387329
There is a need for an improved vaccine for tuberculosis. ESAT-6 is a cardinal vaccine antigen with unique properties and is included in several vaccine candidates in development. ESAT-6 is...